X

Trial Profile

A Phase 2 Study to Evaluate the Safety and Efficacy of SSGJ-707 As First-Line Treatment in Metastatic Colorectal Cancer Patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 707 3SBio (Primary) ; Bevacizumab; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
Indications Colorectal cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Sunshine Guojian Pharmaceutical

Most Recent Events

19 Sep 2024 Status changed from not yet recruiting to recruiting.
09 Aug 2024 Planned number of patients changed from 120 to 130.
09 Aug 2024 Planned initiation date changed from 1 Jul 2024 to 1 Aug 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com